The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.
The Role of the PAX8/PPARgamma Fusion Oncogene in Thyroid Cancer.
复制标题
DOI：
10.1155/2008/672829
复制
发表时间：
2008
期刊：
影响因子：
2.9
通讯作者：
McIver B
中科院分区：
文献类型：
--
作者：
Placzkowski KA;Reddi HV;Grebe SK;Eberhardt NL;McIver B
甲状腺癌不常见，死亡率相对较低。然而，一小部分患者会经历不可阻挡的生长、转移性扩散和死亡。不幸的是，对于这些病人来说，在过去的50年里，治疗方面几乎没有什么重大进展。虽然近年来关于乳头状甲状腺癌的分子遗传事件已经取得了实质性进展，但对更具侵袭性的滤泡性甲状腺癌的了解仍然很少。最近在滤泡性甲状腺癌中发现的PAX8/PPARγ易位促进了PPARγ作为肿瘤抑制因子和潜在治疗靶点的作用。PAX8/PPARγ融合基因似乎是一个致癌基因。它最常在滤泡癌中表达，对野生型PPARγ发挥显性负向作用，并刺激pax8应答启动子的转录。尽管很少有研究评估这些药物的临床影响，但PPARγ激动剂在体外已显示出有希望的结果。
Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPARγ translocation in follicular thyroid carcinoma has promoted progress in the role of PPARγ as a tumor suppressor and potential therapeutic target. The PAX8/PPARγ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPARγ, and stimulates transcription of PAX8-responsive promoters. PPARγ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.
登录
查看更多内容
DOI：
10.1073/pnas.95.15.8806
发表时间：
1998-07-21
影响因子：
11.1
作者：
Elstner, E;Müller, C;Koeffler, HP
通讯作者：
Koeffler, HP
影响因子：
11.5
作者：
Giordano, TJ;Au, AYM;Koenig, RJ
通讯作者：
Koenig, RJ
影响因子：
5.8
作者：
Dwight, T;Thoppe, SR;Zedenius, J
通讯作者：
Zedenius, J
影响因子：
6
作者：
French, CA;Alexander, EK;Kroll, TG
通讯作者：
Kroll, TG
影响因子：
5.8
作者：
Grebe, SKG;McIver, B;Eberhardt, NL
通讯作者：
Eberhardt, NL